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Ultrasound contrast agents have been prima-
rily used for improving left ventricular opacification,
but there are emerging applications that could si-
gnificantly increase their utilization. In addition to
enhancement of endocardial border detection and
Doppler assessment of LV function, contrast echo-
cardiography may be utilized to assess myocardial
perfusion and viability. Until now, detection of my-
ocardial perfusion has been almost exclusively done
with radionuclide tracers. However, since the my-
ocardial contrast echocardiography (MCE) is safe,
less expensive and it can be performed at the pa-
tient’s bedside there is growing interest in this ap-
plication. In addition MCE has increased resolution
when compared with radionuclide imaging (2 mm
vs. 8–12 mm) which permits detection of subendo-
cardial perfusion defects with improved precision.
New data indicate that MCE may be used in the
emergency department to assist in ruling out acu-
te coronary syndromes [1] and that myocardial per-
fusion imaging with ultrasound contrast agents du-
ring dobutamine stress echocardiography is signi-
ficantly better than wall motion analysis alone in
predicting patient’s outcome [2].
MCE has also been used to detect the no-re-
flow phenomenon. The defect detected before pri-
mary PCI can define the region at risk, and the de-
fect detected after successful coronary reperfusion
constitute the area of no-reflow. The improvement
of myocardial perfusion on MCE was predictive of
subsequent improvement in left ventricular func-
tion [3]. Assessment of myocardial perfusion and
the coronary microcirculation with MCE correspon-
ded to evaluation using coronary flow reserve me-
asurements obtained with a coronary artery Dop-
pler wire. MCE may also provide prognostic infor-
mation. In one study of 50 patients with a first
myocardial infarction who received thrombolytic
therapy, the presence of reduced opacification on
MCE, performed on day two, predicted a higher
major cardiac event rate (death, nonfatal infarction,
or admission for congestive heart failure) during
a mean follow up of 22 months (28% vs. 4% in tho-
se with adequate opacification) [4]. In another stu-
dy, patients with a persistent defect in the infarct
zone due to the no-reflow phenomenon, despite the
restoration of TIMI grade 3 flow, had a deteriora-
tion of regional and global systolic dysfunction [5].
Current study published by Wita et al. in this issue
of Folia Cardiologica contributes significant data.
It demonstrates that MCE has high prognostic va-
lue for prediction of functional left ventricular im-
provement in patients with first myocardial infarc-
tion and restored patency of target artery. In fact,
MCE turned out to be significantly better than cur-
rently utilized methods, raising the possibility of
MCE becoming the new “gold standard” for evalu-
ation of no-reflow phenomenon.
The role of myocardial contrast
echocardiography in evaluation
of infarcted, stunned and hibernating
myocardium
Dysfunctional segments of the LV following an
ischemic insult may represent either necrotic, in-
farcted tissue, temporary effect of hypoperfusion
called stunning or chronically hypoperfused, but still
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viable tissue called hibernating myocardium. Pro-
longed occlusion of coronary artery leads to myocar-
dial necrosis which may be easily detected as wall
motion abnormality on echocardiography. However,
if the coronary flow is restored before the onset of
myocardial necrosis, the persistent wall motion
abnormalities may represent viable but not contrac-
tile thus “stunned” myocardium. Since there is
a substantial variability in the time course over
which myocardium recovers from stunning, ranging
from weeks to months, it is good to know that MCE
may be helpful in differentiating these two patterns
of myocardial dysfunction. Stunned myocardium has
homogeneous myocardial contrast, representing
normal blood flow with an intact microvasculature.
Such a pattern implies either that the decrease in
perfusion was not lethal or that reperfusion (either
spontaneous or as a result of intervention) occur-
red prior to necrosis. In this setting, systolic func-
tion is likely to return over the next several weeks
[6–9]. In one study of 96 patients, the positive and
negative predictive value of homogeneous opacifi-
cation for recovery of contractile function at six
months was 47% and 84%, respectively; the positi-
ve predictive value for predicting functional reco-
very was 78% in those who were revascularized [8].
Chronically reduced blood flow may also lead
to a state of persistently impaired myocardial func-
tion with preservation of viability called hibernating
myocardium. Hibernating myocardium can be par-
tially or completely restored to normal by impro-
ving blood flow and/or by reducing demand. Viabi-
lity studies performed to detect hibernating but via-
ble tissue are usually done in high risk patients with
LV dysfunction in order to guide difficult decisions
regarding revascularization. Current techniques
used to determine myocardial viability include sin-
gle photon emission computed tomography
(SPECT) imaging, positron emission tomography
scanning, nuclear magnetic imaging, and low-dose
dobutamine echocardiography. MCE provides si-
multaneous LV function and perfusion information
and offers the advantages of improved image reso-
lution (over SPECT), portability, cost economy, and
practicality. The identification of subnormal flow
(heterogeneous contrast effect) as opposed to no
flow (fixed contrast defect) or normal flow (homo-
geneous contrast) within dysfunctional myocardium
may predict long-term recovery of function follo-
wing the restoration of normal blood supply [10].
Microbubbles may also have therapeutic poten-
tial. Preclinical trials have demonstrated that ultra-
sound-mediated microbubble destruction can be used
to target delivery of genes to the myocardium [11].
Phase 1 clinical trials are under way exploring
whether antisense oligonucleotides, which inhi-
bit c-myc protooncogene can be safely delivered
to stented coronary artery segment with intrave-
nous microbubbles. Microbubbles may also be
used in combination with ultrasound to non-in-
vasively dissolve intravascular thrombi without
the need of a lytic agent [12]. This may be espe-
cially useful in the treatment of acute stroke, and
preclinical trials have demonstrated that intra-
cranial ultrasound and intravenous target micro-
bubbles can successfully recanalize intracranial
thrombi [13].
Myocardial contrast echocardiography is a new
and growing field. It started with the quest for im-
proved echocardiographic resolution and left ven-
tricular endocardial border detection and grew into
the real time assessment of intracardiac blood flow,
myocardial perfusion and viability, and it may pro-
vide a future means for drug delivery and other the-
rapeutic interventions.
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